Developers

We started developing the vaccine when the pre-marketing trials of the first two vaccines had been completed. And we initially took a different path in order to level out those possible changes that occurred in the structure of the so-called S, or spike, protein – the outer protein of the SARS-CoV-2 virus.

As the head of the research and development center, I was assisted by a team who believed in our laboratory: biotechnologists, analysts, research laboratory technicians, documentation specialists. This is a team that works as a single mechanism to quickly solve problems associated with the development. The team has done an enormous work to develop Convacell^®.

My contribution to the Convacell^® project was supervision of the production of protein, a key component of our vaccine.  I believe that participation in such an ambitious project allowed me, first of all, to realize my potential, to use my experience and my knowledge in practice to facilitate the market launch of a real, not merely theoretical, target product, which was useful to the society as a whole and to every person in our country, in particular.